Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy
Adjuvant chemotherapy has been shown to provide survival benefits in patients with breast cancer, but some patients still relapse despite this. There is therefore a need for molecular markers present within the primary tumour that can predict for chemotherapy sensitivity or resistance. Until now, no...
Gespeichert in:
| Veröffentlicht in: | Endocrine-related cancer 2005-07, Vol.12 (Supplement_1), p.S125-S133 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S133 |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | S125 |
| container_title | Endocrine-related cancer |
| container_volume | 12 |
| creator | Barrett-Lee, P J |
| description | Adjuvant chemotherapy has been shown to provide survival benefits in patients with breast cancer, but some patients still relapse despite this. There is therefore a need for molecular markers present within the primary tumour that can predict for chemotherapy sensitivity or resistance. Until now, no single marker has emerged into routine clinical practice, but several candidate pathways are being extensively investigated. This paper summarises the current status of growth factor singalling and p53 function in this context. The data on human epidermal growth factor receptor-2, topoisomerase II and p53 expression in a variety of breast cancer treatment settings are discussed. |
| doi_str_mv | 10.1677/erc.1.01024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68499364</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68499364</sourcerecordid><originalsourceid>FETCH-LOGICAL-b372t-6f7e46dc9c33fe05df4612d55e20b14bd882923524cc4d73772ba4205db1ada3</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpSdI0p97LnHop3ujLst1bCW1aCOSSu5Dl8VrFllxJmyXH_vMq9UKh0J5mYJ73ZXgIecvojqmmucZod2xHGeXyBblgsukq1XL2suyiZhWlbXtOXqf0nVKq2ro-I-dMMSZo212Qn7cxHPMEo7E5REhu7808O78H58GWxVkzQx_RpAzWeIsRjB_A5QRuWUsKgoeIaQ0-IeQANvhH9NmFUgR5wmhWh-kjmEI9OjxCGMFOuITt9vSGvBrNnPDqNC_Jw5fPDzdfq7v72283n-6qXjQ8V2psUKrBdlaIEWk9jFIxPtQ1ctoz2Q9tyzsuai6tlUMjmob3RvIC9swMRlyS91vtGsOPA6asF5cszrPxGA5Jq1Z2nVCygB820MaQUsRRr9EtJj5pRvWzcF2Ea6Z_Cy_0u1PtoV9w-MOeDBeAb8Dk9tPRRdS9C8m6Z0VjkfuPVraF_mL_98kvjdqf6A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68499364</pqid></control><display><type>article</type><title>Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><source>Society for Endocrinology Journals</source><creator>Barrett-Lee, P J</creator><creatorcontrib>Barrett-Lee, P J</creatorcontrib><description>Adjuvant chemotherapy has been shown to provide survival benefits in patients with breast cancer, but some patients still relapse despite this. There is therefore a need for molecular markers present within the primary tumour that can predict for chemotherapy sensitivity or resistance. Until now, no single marker has emerged into routine clinical practice, but several candidate pathways are being extensively investigated. This paper summarises the current status of growth factor singalling and p53 function in this context. The data on human epidermal growth factor receptor-2, topoisomerase II and p53 expression in a variety of breast cancer treatment settings are discussed.</description><identifier>ISSN: 1351-0088</identifier><identifier>EISSN: 1479-6821</identifier><identifier>DOI: 10.1677/erc.1.01024</identifier><identifier>PMID: 16113089</identifier><language>eng</language><publisher>England: BioScientifica</publisher><subject>Antigens, Neoplasm - analysis ; Antigens, Neoplasm - metabolism ; Biomarkers - analysis ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Chemotherapy, Adjuvant ; Conference Papers ; DNA Topoisomerases, Type II - analysis ; DNA Topoisomerases, Type II - metabolism ; DNA-Binding Proteins - analysis ; DNA-Binding Proteins - metabolism ; Drug Resistance, Neoplasm ; Female ; Humans ; Receptor, ErbB-2 - analysis ; Receptor, ErbB-2 - metabolism ; Signal Transduction ; Treatment Outcome ; Tumor Suppressor Protein p53 - analysis ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>Endocrine-related cancer, 2005-07, Vol.12 (Supplement_1), p.S125-S133</ispartof><rights>2005 Society for Endocrinology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b372t-6f7e46dc9c33fe05df4612d55e20b14bd882923524cc4d73772ba4205db1ada3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3936,3937,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16113089$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barrett-Lee, P J</creatorcontrib><title>Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy</title><title>Endocrine-related cancer</title><addtitle>Endocr Relat Cancer</addtitle><description>Adjuvant chemotherapy has been shown to provide survival benefits in patients with breast cancer, but some patients still relapse despite this. There is therefore a need for molecular markers present within the primary tumour that can predict for chemotherapy sensitivity or resistance. Until now, no single marker has emerged into routine clinical practice, but several candidate pathways are being extensively investigated. This paper summarises the current status of growth factor singalling and p53 function in this context. The data on human epidermal growth factor receptor-2, topoisomerase II and p53 expression in a variety of breast cancer treatment settings are discussed.</description><subject>Antigens, Neoplasm - analysis</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Biomarkers - analysis</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Chemotherapy, Adjuvant</subject><subject>Conference Papers</subject><subject>DNA Topoisomerases, Type II - analysis</subject><subject>DNA Topoisomerases, Type II - metabolism</subject><subject>DNA-Binding Proteins - analysis</subject><subject>DNA-Binding Proteins - metabolism</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Humans</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Signal Transduction</subject><subject>Treatment Outcome</subject><subject>Tumor Suppressor Protein p53 - analysis</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>1351-0088</issn><issn>1479-6821</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVpSdI0p97LnHop3ujLst1bCW1aCOSSu5Dl8VrFllxJmyXH_vMq9UKh0J5mYJ73ZXgIecvojqmmucZod2xHGeXyBblgsukq1XL2suyiZhWlbXtOXqf0nVKq2ro-I-dMMSZo212Qn7cxHPMEo7E5REhu7808O78H58GWxVkzQx_RpAzWeIsRjB_A5QRuWUsKgoeIaQ0-IeQANvhH9NmFUgR5wmhWh-kjmEI9OjxCGMFOuITt9vSGvBrNnPDqNC_Jw5fPDzdfq7v72283n-6qXjQ8V2psUKrBdlaIEWk9jFIxPtQ1ctoz2Q9tyzsuai6tlUMjmob3RvIC9swMRlyS91vtGsOPA6asF5cszrPxGA5Jq1Z2nVCygB820MaQUsRRr9EtJj5pRvWzcF2Ea6Z_Cy_0u1PtoV9w-MOeDBeAb8Dk9tPRRdS9C8m6Z0VjkfuPVraF_mL_98kvjdqf6A</recordid><startdate>200507</startdate><enddate>200507</enddate><creator>Barrett-Lee, P J</creator><general>BioScientifica</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200507</creationdate><title>Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy</title><author>Barrett-Lee, P J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b372t-6f7e46dc9c33fe05df4612d55e20b14bd882923524cc4d73772ba4205db1ada3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antigens, Neoplasm - analysis</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Biomarkers - analysis</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Chemotherapy, Adjuvant</topic><topic>Conference Papers</topic><topic>DNA Topoisomerases, Type II - analysis</topic><topic>DNA Topoisomerases, Type II - metabolism</topic><topic>DNA-Binding Proteins - analysis</topic><topic>DNA-Binding Proteins - metabolism</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Humans</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Signal Transduction</topic><topic>Treatment Outcome</topic><topic>Tumor Suppressor Protein p53 - analysis</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barrett-Lee, P J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine-related cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barrett-Lee, P J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy</atitle><jtitle>Endocrine-related cancer</jtitle><addtitle>Endocr Relat Cancer</addtitle><date>2005-07</date><risdate>2005</risdate><volume>12</volume><issue>Supplement_1</issue><spage>S125</spage><epage>S133</epage><pages>S125-S133</pages><issn>1351-0088</issn><eissn>1479-6821</eissn><abstract>Adjuvant chemotherapy has been shown to provide survival benefits in patients with breast cancer, but some patients still relapse despite this. There is therefore a need for molecular markers present within the primary tumour that can predict for chemotherapy sensitivity or resistance. Until now, no single marker has emerged into routine clinical practice, but several candidate pathways are being extensively investigated. This paper summarises the current status of growth factor singalling and p53 function in this context. The data on human epidermal growth factor receptor-2, topoisomerase II and p53 expression in a variety of breast cancer treatment settings are discussed.</abstract><cop>England</cop><pub>BioScientifica</pub><pmid>16113089</pmid><doi>10.1677/erc.1.01024</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1351-0088 |
| ispartof | Endocrine-related cancer, 2005-07, Vol.12 (Supplement_1), p.S125-S133 |
| issn | 1351-0088 1479-6821 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68499364 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection; Society for Endocrinology Journals |
| subjects | Antigens, Neoplasm - analysis Antigens, Neoplasm - metabolism Biomarkers - analysis Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Chemotherapy, Adjuvant Conference Papers DNA Topoisomerases, Type II - analysis DNA Topoisomerases, Type II - metabolism DNA-Binding Proteins - analysis DNA-Binding Proteins - metabolism Drug Resistance, Neoplasm Female Humans Receptor, ErbB-2 - analysis Receptor, ErbB-2 - metabolism Signal Transduction Treatment Outcome Tumor Suppressor Protein p53 - analysis Tumor Suppressor Protein p53 - metabolism |
| title | Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T07%3A28%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Growth%20factor%20signalling%20in%20clinical%20breast%20cancer%20and%20its%20impact%20on%20response%20to%20conventional%20therapies:%20a%20review%20of%20chemotherapy&rft.jtitle=Endocrine-related%20cancer&rft.au=Barrett-Lee,%20P%20J&rft.date=2005-07&rft.volume=12&rft.issue=Supplement_1&rft.spage=S125&rft.epage=S133&rft.pages=S125-S133&rft.issn=1351-0088&rft.eissn=1479-6821&rft_id=info:doi/10.1677/erc.1.01024&rft_dat=%3Cproquest_cross%3E68499364%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68499364&rft_id=info:pmid/16113089&rfr_iscdi=true |